Key Highlights
•
A new MRI technique called SWI-driven Susceptibility Map-weighted Imaging (SMwI) can be used to diagnose early Parkinson’s disease without needing a special, dedicated scan. This provides a practical fallback option for doctors when the more accurate, specialized scan is not available, helping to identify the disease earlier.
Source →
•
Most primary care patients are willing to take a simple blood test to check for Alzheimer’s disease biomarkers, especially if their doctor recommends it and insurance covers the cost. This openness suggests blood tests could become a widely accepted first step in detecting Alzheimer’s, though patients will need support to cope with the emotional impact of a positive result.
Source →
•
The approval of the Alzheimer’s drug lecanemab in the UK has created significant practical challenges for the healthcare system, including how to pay for it and set up the necessary infrastructure for patient testing and monitoring. This highlights the gap between approving a groundbreaking new treatment and actually making it accessible and deliverable to patients in a real-world setting.
Source →
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.
